Am J Transplant, Volume 20, Suppl 3 Archives - Page 87 of 223 - ATC Abstracts

2020 American Transplant Congress
Using Trajectory Analysis to Characterize Trends in OPO Performance with Population-Based Metrics
K. Ross¹, D. Goldberg², R. Lynch¹
¹Emory University, Emory Transplant Center, Atlanta, GA, ²University of Miami, Miami, FL
*Purpose: Identifying the organ procurement organizations (OPOs) with the greatest opportunity to improve donation rates may help increase the number of transplants in the United…
2020 American Transplant Congress
Analysis of 1000 Protocol Kidney Biopsies: Complications, Benefits, and Predictive Potential of Prior Sensitization
M. Eslami¹, J. Patel², S. Karzai¹, D. T. Collins¹, C. Liu¹, J. Jonsson¹, R. Wali¹, J. B. Piper¹
¹Surgery, Inova Fairfax Hospital, Falls Church, VA, ²General Surgery, Pennsylvania State University, State College, PA
*Purpose: Protocol biopsy of kidney transplants can allow for early recognition of treatable findings, both immunologic and non-immunologic. This comes with the risk of biopsy…
2020 American Transplant Congress
Plasma Microbiome Profiles of Liver Transplant Patients with Operational Tolerance
C. Kuscu¹, J. Pierre², I. Lies¹, C. Kuscu¹, A. Bajwa¹, A. Wolen¹, J. Eason¹, B. Ramaswami³, D. Maluf¹, G. Mazariegos³, G. Chalasani³, V. Mas¹
¹James D. Eason Transplant Institute, Department of Surgery, UTHSC, Memphis, TN, ²Department of Pediatrics, UTHSC, Memphis, TN, ³Thomas E. Starzl Transplantation Institute, Children's Hospital of Pittsburgh, UPMC, Pittsburgh, PA
*Purpose: Microbiome has emerged as a key modulator of organ homeostasis and immune system function with altered microbiota and microbiome - host interactions contributing to…
2020 American Transplant Congress
Socio-Demographic Disparities in Access to Organs from HCV-Viremic Donors among HCV-Negative Patients
T. Nguyen¹, W. Williams², M. Sise², P. Reese³, D. Goldberg¹
¹Medicine, University of Miami, Miami, FL, ²Massachusetts General Hospital, Boston, MA, ³University of Pennsylvania, Philadelphia, PA
*Purpose: The success of pilot trials of transplanting organs from hepatitis C virus (HCV) viremic donors into HCV-negative recipients (HCV D+/R-) has led to an…
2020 American Transplant Congress
Long-Term Outcomes of Patients with Epstein-barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in an Expanded Access Program Study
S. Prockop¹, R. Reshaf², D. Tsai³, N. Bunin⁴, R. Abu-Arja⁵, K. Mahadeo⁶, W. Weng⁷, K. Van Besien⁸, D. Loeb⁹, S. Dwivedy Nasta¹⁰, E. Nemecek¹¹, M. Hiremath¹², S. Yue¹², Y. Sun¹², W. Navarro¹², S. Nikiforow¹³
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Loxo Oncology, Stamford, CT, ⁴The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶MD Anderson Cancer Center, Houston, TX, ⁷Stanford University School of Medicine, California, CA, ⁸Weill Cornell Medical College, New York, NY, ⁹Children's Hospital at Montefiore, Bronx, NY, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Oregon Health & Science University, Portland, OR, ¹²Atara Biotherapeutics, New York, NY, ¹³Dana Farber Cancer Institute, Boston, MA
*Purpose: There is a need for effective, well‑tolerated therapies in pts who develop Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ (SOT) or…
2020 American Transplant Congress
Long-Term Outcomes with Islet Alone and Islet-after-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation Consortium
M. R. Rickels¹, T. L. Eggerman², L. Bayman³, J. C. Qidwai³, R. Alejandro⁴, N. D. Bridges⁵, B. J. Hering⁶, J. F. Markmann⁷, P. A. Senior⁸, L. G. Hunsicker³
¹Institute for Diabetes, Obesity & Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, ³University of Iowa, Iowa City, IA, ⁴University of Miami, Miami, FL, ⁵National Institute of Allergy and Infectious Disease, Bethesda, MD, ⁶University of Minnesota, Minneapolis, MN, ⁷Massachusetts General Hospital, Boston, MA, ⁸University of Alberta, Edmonton, AB, Canada
*Purpose: Phase 3 studies of islet transplant alone (ITA; n=48) and islet-after-kidney (IAK; n=24) transplantation in type 1 diabetes complicated by severe hypoglycemic events (SHE)…
2020 American Transplant Congress
Orthogonal IL-2 Cytokine-Receptor Pair Capable of Selective Expansion of Regulatory T Cells Facilitates Alloengraftment
T. Hirai¹, F. Simonetta², L. L. Su³, L. Picton³, J. Baker², J. Lin⁴, P. Li⁴, W. J. Leonard⁴, K. C. Garcia³, R. S. Negrin²
¹Department of Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA, ³Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University, Stanford, CA, ⁴Laboratory of Molecular Immunology, National Institutes of Health, Bethesda, MD
*Purpose: Adoptive transfer of regulatory T cells (Tregs) has been shown to improve alloengraftment in animal models. However, ex vivo Treg expansion for the purpose…
2020 American Transplant Congress
Frailty Prevalence among Younger and Older Kidney Transplant Candidates and Recipients
X. Chen¹, N. Chu¹, J. Walston², D. Segev¹, M. McAdams DeMarco¹
¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Frailty is associated with decreased access to kidney transplantation and poor post kidney transplant (KT) outcomes. This paper aims to explore the prevalence and…
2020 American Transplant Congress
Can Predonation Ambulatory Blood Pressure Monitoring Predict Postdonation Renal Function?
M. Mohamed Ahmed, M. Posadas Salas, D. Taber, V. Rao, K. Soliman, M. Casey
Medical University of South Carolina, Charleston, SC
*Purpose: Data on living kidney donor outcomes are of topical interest to the transplant community. Despite thorough pre-donation screening and risk assessment, a minority of…
2020 American Transplant Congress
Liver Transplantation of Hepatitis C Viremic Donors to Hepatitis C Naive Recipients
R. K. Gilroy, F. Lopez-Verdugo, G. Harmston, S. Fujita, M. E. Boschert, I. Zendejas, E. J. Frech, A. Gagnon, R. Jones, J. Krong, S. Sell, S. Dow, L. Lindberg, M. Rodriguez-Davalos, D. Alonso
Transplant Services, Intermountain Healthcare, Murray, UT
*Purpose: This study describes outcomes, out to 3 years, at one of the first centers in the United States to begin Hepatitis C Virus (HCV)-Nucleic…